Cevimeline

• CAT Number: I000333
• CAS Number: 107233-08-9
• Molecular Formula: C10H17NOS
• Molecular Weight: 199.32
• Purity: ≥95%
• Target: Muscarinic Receptor
• Solubility: in DMSO > 10 mM
• Storage: Store at -20°C
• InChI: 1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m0/s1
• InChIKey: WUTYZMFRCNBCHQ-WPRPVWTQSA-N
• SMILES: CC1OC2(CN3CCC2CC3)CS1

Cevimeline (CAT: I000333) is a medication primarily used for the treatment of dry mouth (xerostomia) associated with Sjögren’s syndrome, an autoimmune disorder. It is a muscarinic receptor agonist that stimulates the secretion of saliva by binding to and activating muscarinic receptors in the salivary glands. By increasing saliva production, cevimeline helps alleviate the symptoms of dry mouth, such as difficulty swallowing, speaking, and chewing. It may also improve dryness in other mucous membranes, such as the eyes.

Reference

1. Nihon Yakurigaku Zasshi. 2002 Oct;120(4):253-8.

[Cevimeline hydrochloride hydrate (Saligren capsule 30 mg): a review of its
pharmacological profiles and clinical potential in xerostomia].

Shiozawa A(1).

Author information:
(1)Scientific Affairs Department Pharmaceuticals Group, Nippon Kayaku Co. Ltd.,
Tokyo Fujimi Bldg., 11-2, Fujimi 1-Chome, Chiyoda-ku, Tokyo 102-8172, Japan.


Cevimeline hydrochloride hydrate is a muscarinic receptor agonist with a chemical
structure of a quinuclidine. Intraduodenal administration of cevimeline
hydrochloride hydrate dose-dependently increased salivary secretion in normal
mice and rats, two strains of autoimmune disease mice, and X-irradiated rats. The
clinical efficacy of the cevimeline hydrochlide hydrate at 30 mg t.i.d. during 4
weeks has been demonstrated in double blind comparative study with placebo. In
addition, its treatments in 52 weeks have increased salivary flow and improved
subjective and objective symptoms of patients with xerostomia in Sjögren/’s
syndrome.

2. Adv Exp Med Biol. 2002;506(Pt B):1107-16.

Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren/’s
syndrome.

Fox RI(1).

Author information:
(1)Allergy and Rheumatology Clinic, Scripps Memorial Hospital and Research
Foundation, La Jolla, California, USA.